Journal of Substance Abuse Treatment

Papers
(The TQCC of Journal of Substance Abuse Treatment is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Increased availability of telehealth mental health and substance abuse treatment for peripartum and postpartum women: A unique opportunity to increase telehealth treatment92
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study83
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data81
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic74
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?73
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction64
Racial disparities in use of non-emergency outpatient care by Medicaid-eligible adults after release from prison: Wisconsin, 2015–201762
Substance use among women who are pregnant: Examining treatment completion by race and ethnicity55
Employing the Risk-Need-Responsivity (RNR) model and predicting successful completion in an alternative drug court program: Preliminary findings from the Orleans Parish Drug Court55
COVID-19 and treating incarcerated populations for opioid use disorder47
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups46
Effects of a cannabis use disorder text message–delivered treatment on young adult alcohol misuse: Differential effects by gender46
Patterns of enrollment in a New Orleans women's substance use rehabilitation center45
C2: editorial board45
From there to here: A journey through substance use disorder, prison, and recovery44
TOC (update)43
Mapping recovery: A qualitative node map approach to understanding factors proximal to relapse among adolescents in a recovery high school42
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program41
C2: editorial board39
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder39
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–202038
C2: editorial board37
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs36
TOC (update)36
Emotion dysregulation and hazardous drinking in relation to suicidal ideation among Spanish-speaking Latinx daily-smokers35
Variability in outcomes and quality-of-care indicators across clinics participating in a large smoking-cessation program34
Suicidal behavior, opioid use disorder, and behavioral health treatment: Prevalence and correlates among adults in the United States 2015–201833
Timing of smoking cessation treatment integrated into outpatient treatment with medications for opioid use disorder: Feasibility trial32
JSAT call for papers for special issue: Stimulant use disorder32
C2: editorial board32
A delicate compromise: Striking a balance between public safety measures and the psychosocial needs of staff and clients in residential substance use disorder treatment amid COVID-1932
Optimizing outpatient treatment outcomes among methamphetamine-using gay and bisexual men through a computerized depression intervention31
Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine31
Influence of a national transgender health care directive on receipt of alcohol-related care among transgender Veteran Health Administration patients with unhealthy alcohol use30
Rates and predictors of brief intervention for women veterans returning from recent wars: Examining gaps in service delivery for unhealthy alcohol use29
C2: editorial board29
Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management28
Opioid-related emergencies in New York City after the Great Recession28
Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only27
The systematic development of a mobile phone–delivered brief intervention for hazardous drinking in India27
Motivational interviewing telephone counseling to increase postpartum maintenance of abstinence from tobacco26
Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program26
Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis25
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings25
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail25
Mechanisms of change in an adapted marijuana e-CHECKUP TO GO intervention on decreased college student cannabis use25
Public injecting and its association with mental health and other drug-related outcomes among people who inject drugs in Iran24
Poking the bear: The inapplicability of the RNR principles for justice-involved women24
Association between discharges against medical advice and readmission in patients treated for drug injection-related skin and soft tissue infections23
Predicting longitudinal service use for individuals with substance use disorders: A latent profile analysis23
Barriers and facilitators of implementing integrated interventions for alcohol misuse and intimate partner violence: A qualitative examination with diverse experts23
Traditions and Connections for Urban Native Americans (TACUNA): Utilizing community-based input to develop an opioid prevention intervention for urban American Indian/Alaska Native emerging adults23
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids22
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma22
Long-acting depot buprenorphine in people who are homeless: Views and experiences22
The impact of race, gender, and heroin use on opioid addiction stigma22
Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series21
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he21
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support21
Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration21
Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol21
Law enforcement assisted diversion: Qualitative evaluation of barriers and facilitators of program implementation21
Contingency management for treatment attendance: A meta-analysis21
Acceptance of medications for opioid use disorder in recovery housing programs in Missouri21
The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review21
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study20
Peer recovery services for persons returning from prison: Pilot randomized clinical trial investigation of SUPPORT20
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health20
Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey20
Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada20
Impacts of COVID-19 on residential treatment programs for substance use disorder19
The intersection of race and opioid use disorder treatment: A quantitative analysis19
Racial disparities in linkage to care among patients with substance use disorders19
Reducing tobacco use in substance use treatment: An intervention to promote tobacco-free grounds19
Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees19
Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine18
Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose18
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?18
Predictors and moderators of marijuana and heavy alcohol use outcomes in adolescents treated for co-occurring substance use and psychiatric disorders in a randomized controlled trial18
Diagnostic remission of substance use disorders: Racial differences and correlates of remission in a nationally representative sample17
Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention17
Corrigendum to “Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse” [Journal of Substance Abuse Treatment 131 (2021) 108447]17
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder17
Race, ethnicity, and emergency department post-overdose care17
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island17
Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida17
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals17
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic17
Corrigendum to “Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study” [Journal of Substance Abuse Treatment 130 (2021) 108415]17
An efficacy trial of adaptive interventions for alcohol use disorder17
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder16
Clinical symptoms and personality traits predict subpopulations of treatment-seeking substance users16
Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting16
Utility of interactive voice response self-monitoring in stabilizing initial change during natural recovery attempts among persons with alcohol use disorder16
Substance use and criminogenic thinking: Longitudinal latent class analysis of veterans with criminal histories16
Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review16
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-1916
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services16
Not in my treatment center: Leadership's perception of barriers to MOUD adoption16
Goal setting and monitoring with alcohol and other drug use disorders: Principles and practices16
Post–residential treatment outpatient care preferences: Perspectives of youth with opioid use disorder15
TOC (update)15
An intervention pilot to facilitate harm reduction service decentralization in Vietnam15
Kindness, connection, and science15
Multimorbidity classes indicate differential patterns of health care engagement among people who inject drugs15
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review15
TOC (update)15
C2: editorial board15
C2: editorial board14
COVID-19 surveillance and Black American substance use disorder: An examination of data and policy14
Beliefs related to health care incentives: Comparison of substance use disorder treatment providers, medical treatment providers, and a public sample14
Motherhood, substance use and peer support: Benefits of an integrated group program for pregnant and postpartum women14
Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use14
Using daily diary methods to understand how college students in recovery use social support14
C2: editorial board14
TOC (update)14
TOC (update)14
A cohort study examining changes in treatment patterns for alcohol use disorder among commercially insured adults in the United States during the COVID-19 pandemic14
Guidelines for authors14
C2: editorial board14
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated14
Sociodemographic and clinical correlates of cannabis dependence among Israeli combat veterans14
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts14
Drug and sexual HIV-risk behaviors among adolescents and young adults with opioid use disorder14
Perspectives on electronic portal use among patients treated with medications for opioid use disorder in primary care14
Teaching residents to prescribe buprenorphine for opioid use disorder: Insights from a community-based residency program14
‘They don't actually join the dots’: An exploration of organizational change in Irish opiate community treatment services13
TOC (update)13
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder13
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data13
C2: editorial board13
Comparative outcomes for Black children served by the Sobriety Treatment and Recovery Teams program for families with parental substance abuse and child maltreatment13
The opioid epidemic: Mobilizing an academic health center to improve outcomes13
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail13
SBIRT administered by mental health counselors for hospitalized adults with substance misuse or disordered use: Evaluating hospital utilization and costs13
Characterizing nicotine withdrawal in smokers experiencing homelessness13
Gender differences in patient outcomes following drug abuse treatment in Afghanistan: Results from a new evaluation13
Adaptations to substance use disorder monitoring by physician health programs in response to COVID-1913
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic12
Pre-incarceration polysubstance use involving opioids: A unique risk factor of postrelease return to substance use12
Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic12
Correlates of disparities in syringe return ratios: A cross-sectional study of a syringe services program in New York12
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?12
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up12
Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outp12
Deaths associated with opioids, race and ethnicity, and years of potential life lost in Washington State12
Internalizing and externalizing subtypes in female patients with co-occurring post-traumatic stress disorder and substance use disorders12
Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation12
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network12
Patterns and contexts of polysubstance use among young and older adults who are involved in the criminal legal system and use opioids: A mixed methods study12
Predictors of therapeutic alliance, treatment feedback, and clinical outcomes among African American women in treatment for co-occurring PTSD and SUD12
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic12
0.1155571937561